HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and raises the price target from $23 to $27.
HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and raises the price target from $23 to $27.